• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Feasibility of a comprehensive medication review to improve medication use for patients with cancer and comorbid conditions.综合药物评估改善合并症癌症患者药物使用的可行性。
Support Care Cancer. 2022 Dec;30(12):10111-10116. doi: 10.1007/s00520-022-07413-8. Epub 2022 Oct 20.
2
Comprehensive medication review service by embedded pharmacists in primary care: Innovations and impact.基层医疗机构中嵌入药师的全面药物审查服务:创新与影响。
J Am Pharm Assoc (2003). 2022 Mar-Apr;62(2):580-587.e1. doi: 10.1016/j.japh.2021.09.015. Epub 2021 Oct 2.
3
In-home comprehensive medication reviews for adults with intellectual or developmental disability: A pilot study.智障或发育障碍成人的家庭综合药物评估:一项试点研究。
J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):e279-e291. doi: 10.1016/j.japh.2020.03.019. Epub 2020 Apr 23.
4
Access to Medical Records' Impact on Community Pharmacist-Delivered Medication Therapy Management: A Pilot From the Medication Safety Research Network of Indiana (Rx-SafeNet).获取医疗记录对社区药剂师提供的药物治疗管理的影响:印第安纳州药物安全研究网络(Rx-SafeNet)的一项试点研究
J Pharm Pract. 2018 Dec;31(6):642-650. doi: 10.1177/0897190017735422. Epub 2017 Oct 10.
5
Pharmacist medication therapy management in home health care: Investigation of a sustainable practice model.家庭医疗保健中的药剂师药物治疗管理:一种可持续实践模式的调查
J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4S):S64-S68. doi: 10.1016/j.japh.2018.04.028. Epub 2018 Jun 7.
6
Impact of Pharmacist-Conducted Comprehensive Medication Reviews for Older Adult Patients to Reduce Medication Related Problems.药师开展的综合用药评估对老年患者减少用药相关问题的影响。
Pharmacy (Basel). 2017 Dec 31;6(1):2. doi: 10.3390/pharmacy6010002.
7
Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer.实施由药剂师主导的个体化药物评估与规划(iMAP)干预措施,以减少老年癌症患者的药物相关问题。
J Geriatr Oncol. 2017 Jul;8(4):296-302. doi: 10.1016/j.jgo.2017.04.005. Epub 2017 May 13.
8
Factors affecting Medicare Part D beneficiaries' decision to receive comprehensive medication reviews.影响 Medicare Part D 受益人的接受全面药物审查决定的因素。
J Am Pharm Assoc (2003). 2013 Sep-Oct;53(5):482-7. doi: 10.1331/JAPhA.2013.12233.
9
Pharmacist-led medication review to identify medication-related problems in older people referred to an Aged Care Assessment Team: a randomized comparative study.药剂师主导的药物审查,以确定转介至老年护理评估团队的老年人的药物相关问题:一项随机对照研究。
Drugs Aging. 2012 Jul 1;29(7):593-605. doi: 10.1007/BF03262276.
10
Prioritization of patients for comprehensive medication review by a clinical pharmacist in family medicine.家庭医学中临床药师对患者进行全面药物评估的优先排序。
J Am Board Fam Med. 2015 May-Jun;28(3):418-24. doi: 10.3122/jabfm.2015.03.140303.

引用本文的文献

1
Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists' practices.化疗患者的最佳高血糖阈值:肿瘤学家实践的横断面研究
Support Care Cancer. 2024 Aug 1;32(8):563. doi: 10.1007/s00520-024-08756-0.
2
Toxicity Derived from Interaction between Natural Compounds and Cancer Therapeutic Drugs Metabolized by CYP3A4: Lessons Learned from Two Clinical Case Reports.天然化合物与 CYP3A4 代谢的癌症治疗药物相互作用导致的毒性:来自两个临床病例报告的经验教训。
Int J Mol Sci. 2023 Nov 5;24(21):15976. doi: 10.3390/ijms242115976.
3
Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial.肿瘤学家、药剂师和糖尿病专家三方合作对开始化疗的糖尿病患者管理的影响:ONCODIAB试验
Cancers (Basel). 2023 Sep 13;15(18):4544. doi: 10.3390/cancers15184544.
4
Oncologists' responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study.肿瘤学家在管理癌症化疗患者高血糖方面的责任、舒适度和知识:一项横断面研究。
Support Care Cancer. 2023 Jul 8;31(8):450. doi: 10.1007/s00520-023-07927-9.

本文引用的文献

1
Medication risks in older patients (70 +) with cancer and their association with therapy-related toxicity.老年癌症患者(70 岁以上)的药物风险及其与治疗相关毒性的关系。
BMC Geriatr. 2022 Aug 30;22(1):716. doi: 10.1186/s12877-022-03390-z.
2
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers.血液癌症老年患者药物滥用和潜在不适当药物与虚弱的关系。
J Natl Compr Canc Netw. 2022 Aug;20(8):915-923.e5. doi: 10.6004/jnccn.2022.7033.
3
Medication-related problems identified by pharmacists in an enhanced medication therapy management model.药剂师在强化药物治疗管理模式中识别出的与药物相关的问题。
Am J Manag Care. 2021 Sep;27(16 Suppl):S292-S299. doi: 10.37765/ajmc.2021.88754.
4
Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy.接受静脉化疗的老年癌症患者多重用药与住院治疗之间的关系。
J Geriatr Oncol. 2020 May;11(4):579-585. doi: 10.1016/j.jgo.2020.03.001. Epub 2020 Mar 19.
5
Patient perspectives on primary care and oncology care coordination in the context of multiple chronic conditions: A systematic review.患者对多种慢性病背景下初级保健和肿瘤学护理协调的看法:系统评价。
Res Social Adm Pharm. 2020 Aug;16(8):1003-1016. doi: 10.1016/j.sapharm.2019.11.014. Epub 2019 Nov 26.
6
Chronic Comorbidity Among Patients With Cancer: An Impetus for Oncology and Primary Care Collaboration.癌症患者的慢性合并症:肿瘤学与初级保健合作的动力。
JAMA Oncol. 2019 Aug 1;5(8):1099-1100. doi: 10.1001/jamaoncol.2019.1601.
7
Provider Involvement in Care During Initial Cancer Treatment and Patient Preferences for Provider Roles After Initial Treatment.在初始癌症治疗期间的提供者参与度和初始治疗后患者对提供者角色的偏好。
J Oncol Pract. 2019 Apr;15(4):e328-e337. doi: 10.1200/JOP.18.00497. Epub 2019 Mar 11.
8
Implementing personalized pathways for cancer follow-up care in the United States: Proceedings from an American Cancer Society-American Society of Clinical Oncology summit.美国实施癌症随访护理的个性化路径:美国癌症协会-美国临床肿瘤学会峰会会议记录。
CA Cancer J Clin. 2019 May;69(3):234-247. doi: 10.3322/caac.21558. Epub 2019 Mar 8.
9
Correspondence between primary and secondary care about patients with cancer: a Delphi consensus study.初级保健和二级保健之间关于癌症患者的沟通:德尔菲共识研究。
Support Care Cancer. 2019 Nov;27(11):4199-4205. doi: 10.1007/s00520-019-04712-5. Epub 2019 Mar 1.
10
Cancer Survivorship Care in Advanced Primary Care Practices: A Qualitative Study of Challenges and Opportunities.高级初级保健实践中的癌症生存者护理:挑战和机遇的定性研究。
JAMA Intern Med. 2017 Dec 1;177(12):1726-1732. doi: 10.1001/jamainternmed.2017.4747.

综合药物评估改善合并症癌症患者药物使用的可行性。

Feasibility of a comprehensive medication review to improve medication use for patients with cancer and comorbid conditions.

机构信息

Michigan Oncology Quality Consortium (MOQC) and Michigan Institute for Care Management and Transformation (MICMT), 4251 Plymouth Road Arbor Lakes, Building 3, Floor 3, Ann Arbor, MI, 48105, USA.

Johns Hopkins Department of Pharmacy, Baltimore, MD, USA.

出版信息

Support Care Cancer. 2022 Dec;30(12):10111-10116. doi: 10.1007/s00520-022-07413-8. Epub 2022 Oct 20.

DOI:10.1007/s00520-022-07413-8
PMID:36264359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9715514/
Abstract

PURPOSE

A focus on oral medications for patients receiving care from both oncologists and primary care providers elicits an opportunity for improvement in patient outcomes. The purpose of this pilot study was to explore the feasibility and appropriateness of a comprehensive medication review (CMR) by a primary care pharmacist in a population of patients with cancer and chronic conditions.

METHODS

Adult patients who received both cancer and primary care at Michigan Medicine, received active systemic cancer treatment, and had a comorbid condition of diabetes, hypertension, chronic heart failure, depression, and/or anxiety were eligible to receive a CMR by the primary care clinical pharmacist. Data collected included number eligible for the CMR (feasibility), patient demographics, medication-related problems (MRPs) and medication interventions (appropriate), number of patients requiring follow-up with the clinical pharmacist or physician, and pre/post-intervention changes in A1c and BP, as applicable.

RESULTS

Of the 96 patients that met inclusion criteria, 55 patients (57%) received a CMR. Pharmacists provided 66 instances of patient education and identified 22 medication-related problems (MRPs) in 15 (27%) of patients. After CMRs were completed, 22 patients (40%) were referred to primary care pharmacists or physician providers for ongoing care.

CONCLUSION

A CMR was feasible and appropriate for patients with chronic conditions receiving treatment for cancer.

摘要

目的

关注同时接受肿瘤学家和初级保健提供者护理的患者的口服药物,为改善患者结局提供了机会。本试点研究的目的是探索在癌症和慢性病患者群体中,由初级保健药剂师进行全面药物审查(CMR)的可行性和适宜性。

方法

在密歇根医学中心接受癌症和初级保健治疗、接受积极的全身癌症治疗且患有糖尿病、高血压、慢性心力衰竭、抑郁和/或焦虑等合并症的成年患者有资格接受初级保健临床药剂师的 CMR。收集的数据包括有资格进行 CMR 的患者人数(可行性)、患者人口统计学特征、药物相关问题(MRP)和药物干预(适当性)、需要临床药剂师或医生随访的患者人数,以及适当时 A1c 和 BP 的干预前后变化。

结果

在符合纳入标准的 96 名患者中,有 55 名(57%)患者接受了 CMR。药剂师提供了 66 次患者教育,并在 15 名(27%)患者中发现了 22 个药物相关问题(MRP)。CMR 完成后,22 名(40%)患者被转介给初级保健药剂师或医生提供者进行持续治疗。

结论

CMR 对于接受癌症治疗的慢性病患者是可行且适宜的。